pcc Practice Builder™ Emerges as a Growth Engine for Medical Practices in 2026 
Single Use Support Further Expands Into US Market
Single Use Support, leading provider of fluid management and freeze-thaw logistic solutions for the biopharmaceutical industry, is excited to announce...
Standard BioTools to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., June 14, 2023 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq: LAB), driven by a bold purpose – Unleashing...
HCW Biologics is Granted Third Fundamental Patent: U.S. Patent for Methods of Treating Age-Related Disorders
Allowed Methods of Use Claims Directed to Administering HCW9218 to Treat Cancer, Including Killing or Reducing the Number of Senescent...
Immix Biopharma Completes $5 Million At-The-Market Equity Offering Program
Participating institutional investors include Bridgewest GroupLOS ANGELES, June 14, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc., (Nasdaq:IMMX) (“ImmixBio”, “Company”, “We”...
Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas
Blue Water Biotech Expands Commercial Portfolio by Acquiring Six FDA-Approved Drugs Across Various Treatment Areas Blue Water Biotech Expands Commercial...
Augmedix Extends Term Loan Facility and Finalizes Terms for Equity Line of Credit
Balance Sheet Initiatives Bolster Financial Strength as Company Scales Business Towards Cash Flow Break-EvenSAN FRANCISCO, June 14, 2023 (GLOBE NEWSWIRE)...
EvolveImmune Therapeutics Enters into Strategic Research Collaboration with Kennedy Institute of Rheumatology
Collaboration with Researchers at University of Oxford to Utilize State-of-the-Art Technology to Characterize Immune Synapse Formation Mediated by First-In-Category EVOLVE...
Ventyx Biosciences Announces Initiation of Dosing in a Phase 1 Trial of VTX3232, a Novel CNS-Penetrant NLRP3 Inhibitor
Topline data from the Phase 1 SAD/MAD trial of VTX3232 are expected in H1 2024ENCINITAS, Calif., June 14, 2023 (GLOBE...
Nurix Therapeutics Presents Data from Studies of Its Targeted Protein Degraders in B Cell Malignancies and Initiates Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications
Initiation of NX-2127 Phase 1b expansion cohort in patients with diffuse large B cell lymphoma (DLBCL) was informed by a...
Plus Therapeutics to Participate in the 2023 Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
AUSTIN, Texas, June 14, 2023 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted...
Tilray Brands Expands Beer Portfolio and Launches Good Supply Light Beer
Tilray Introduces New Easy-Drinking Light Beer Brand, Good Supply, in the U.S. Good Supply Easy Lager is Perfectly Chilled and...
Applied UV’s Subsidiary, LED Supply Co., and Its FORTUNE® 500 Technology Partner Awarded Approximately $0.8 million Contract for Comprehensive Lighting & Building Controls Solution for Global Auto Manufacturer’s U.S. Facility
MOUNT VERNON, NY, June 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Applied UV, Inc. (Nasdaq: AUVI) (“Applied UV” or...
Jaden Smith to Speak at World’s Largest Psychedelic Science Conference
Multi-hyphenate entertainer, entrepreneur, advocate, and musician to speak about psychedelic medicine, healing, and mental healthDENVER, June 14, 2023 (GLOBE NEWSWIRE)...
Monopar to Participate in the Maxim Group’s Healthcare Virtual Conference
WILMETTE, Ill., June 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing...
Kura Oncology Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants
SAN DIEGO, June 14, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing...
Eagle Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) and Fast-Track Designation for CAL02, Providing Five-Year Exclusivity Extension
With QIDP, Eagle expects to receive eight or ten years of regulatory exclusivity upon NDA approval– Company believes CAL02 is a...
Castellum, Inc. Announces More Aggressive Cost Reduction Plan; Comments on Stock Trading Price
Castellum, Inc. Announces More Aggressive Cost Reduction Plan; Comments on Stock Trading Price Castellum, Inc. (the “Company”) (NYSE American: CTM)...
Enterome’s new OncoMimics™ immunotherapy, EO2463, demonstrates early efficacy and favorable safety in Phase 1/2 trial for indolent non-Hodgkin lymphoma
EO2463 uniquely targets four distinct B cell markers to maximize tumor killing and prevent immune escape, generating fast, strong and...
Philips’ direct-to-angio stroke pathway: new analysis demonstrates substantial cost savings in addition to improved patient outcomes
Philips Neuro suite June 14, 2023 Economic analysis of cost of Vall d’Hebron University Hospital Stroke Unit shows direct-to-angio stroke...
CancerVAX Launches $10 Million Funding Round
Proceeds from the SEC qualified Reg A+ offering will allow the Company to continue work on its breakthrough cancer treatmentsLEHI,...